Loading annual review details
ResMed Inc. (RMD)FY2026 investor yearly review
Across FY2026, ResMed leaned into accelerating patient flow through devices, masks, and digital “concierge” software while repeatedly tightening the cost engine behind gross margin expansion. In parallel, management broadened the product roadmap (fabric masks, AI coaching) and executed portfolio changes (Noctrix acquisition and MatrixCare divestiture) to sharpen focus.
Overall investor read
Solid delivery with execution sensitivity
Management kept showing operating leverage and cash generation while funding an ecosystem expansion; Q4 also added portfolio and recall-related complexity.
Primary financial signal
$1.65B Free cash flow
FY2026 cash generation stayed robust even as the year included acquisitions and portfolio actions, supporting ongoing reinvestment and capital returns.
Primary call signal
Pathway optimization became the center of gravity
Management repeatedly tied growth to top-of-funnel awareness, middle-of-funnel testing/setup, and day-90 adherence via RCS and diagnostics.
Key outcomes that summarize ResMed’s year of delivery, leverage, and capital strength.
Revenue
Revenue grew 9.9% on the year as management expanded the sleep ecosystem.
Gross margin
61.1% gross margin reflects sustained supply chain productivity and efficiency focus.
Operating margin
Operating margin at 33.4% highlights continued operating leverage amid investment.
Net income
Net income rose with earnings growth outpacing revenue through the year.
Operating cash flow
Operating cash flow improved to $1.81B, reinforcing management’s reinvest/cap return balance.
Free cash flow
Free cash flow margin was 29.2%; management still funded acquisitions and buybacks.
Capital returns
Capital returns supported shareholder payouts while management pursued ecosystem investments.
ResMed built FY2026 around ecosystem momentum—devices, masks, and RCS—while management sustained gross margin progress and used free cash flow to reset its portfolio.
Care pathway
Management framed growth as moving patients through awareness to testing/setup and then into durable day-90 adherence. Across Q1–Q4, they linked GLP-1 and wearables to top-of-funnel inflow and emphasized tools like VirtuOx/NightOwl and RCS workflows to keep conversion from stalling.
Product execution
Quarter-by-quarter materiality and tone for annual transcript themes.
Scroll horizontally to see more columns.
| Theme | Q1 | Q2 | Q3 | Q4 | Next monitor |
|---|---|---|---|---|---|
| Sleep pathway conversion scaled with GLP-1 and wearables | Positive GLP-1 and wearables pull patients into PCP funnel, management emphasized conversion. |
ResMed improved the execution cadence of cost and adherence levers while tightening the portfolio’s growth focus; the main challenge was maintaining gross margin headroom as inflation and special charges showed up in Q4.
Management consistently tied gross margin improvement to component, manufacturing, and logistics initiatives. Even with Q3 pressure points, they emphasized a continued pipeline to protect accretion through 2030.
Throughout Q1–Q4, management highlighted AirTouch fabric mask launches and connected them to adherence outcomes, including reported 6% higher 90-day compliance for AirTouch N30i versus silicone equivalents.
FY2026 narrative progressed from strong mask/RCS launches and margin expansion (Q1) into deeper pathway and GLP-1 evidence (Q2), then added Noctrix and expanded adherence data (Q3), culminating in portfolio reshaping and 2027 guidance with Astral headwinds (Q4).
Productivity offsetting inflation with resilient cash flow
Early-year results emphasized operating leverage and mask/AI launches, mid-year deepened the patient-funnel evidence (including GLP-1 and clinician education), and year-end paired portfolio reshaping with explicit FY2027 headwinds.
Management highlighted fabric-mask launches (AirTouch F30i variants), pipeline-based gross margin expansion, and portfolio management work in RCS (shifting investment toward higher-growth SaaS). Q1 also set the stage for acceleration in mask and RCS categories later in the year.
Read earnings transcriptResMed continued to show strong devices and masks growth with operational leverage, while management broadened the pathway narrative: D2C campaigns, PCP CME expansion, and claims-based evidence tying GLP-1 exposure to higher PAP start rates and more durable resupply behavior.
Topics to watch as ResMed moves from FY2026 execution into FY2027 integration, margin maintenance, and pathway scaling.
Management ties GLP-1-driven awareness to PAP starts and durable resupply; estimates may depend on persistence beyond the initial start window.
Track claims and management’s start-rate/resupply-rate figures at 1 and 3 years, plus talk around pills vs injectables.
Fabric masks are repeatedly linked to higher 90-day compliance, which management calls a key lifetime-value driver for multiple stakeholders.
ResMed used multiple quarters to connect product innovation to measurable adherence behavior. Fabric masks (AirTouch portfolio) were linked to higher 90-day compliance, and AI elements in myAir (Dawn/Comfort Match) were described as support that reduces friction and improves long-term persistence.
Margin quality
Across the year, management repeatedly attributed gross margin expansion to supply chain optimization—freight shifts, procurement/manufacturing efficiencies, and distribution network improvements. Q3 also acknowledged component and fuel pressures, but management still emphasized a continuing pipeline of offsetting actions.
Capital allocation
ResMed described portfolio management as an ongoing process: investing more in higher-growth SaaS platforms within RCS while divesting lower-fit components. In Q3–Q4, management added Noctrix to broaden the sleep-health device platform and announced MatrixCare divestiture to accelerate mix and execution.
Three-year claims data framed GLP-1 as tailwind to PAP adherence.
Positive Real-world analyses linked PAP-plus-GLP-1 scripts to higher resupply. |
Positive Oura and wearables integration plus CPAP start timing strengthened funnel thesis. |
| Track the pace of PAP starts after GLP-1, and follow resupply cadence at 1 and 3 years. |
| Fabric mask portfolio and AI support targeted for adherence uplift | Positive F30i Comfort and Clear launches extended AirTouch fabric strategy. | Positive Comfort Match beta positioned AI comfort settings to improve adherence. | Positive Real-world data showed AirTouch N30i drove higher 90-day compliance. | Mixed AI coach inquiries rose, but gross margin faced inflation drag and recall costs. | Monitor 90-day compliance references for fabric masks and myAir AI engagement metrics. |
| Supply chain productivity offset inflation and protected gross margin | Positive 280 bps gross margin expansion tied to components and logistics efficiencies. | Positive 310 bps gross margin expansion reinforced margin improvement flywheel. | Mixed Management acknowledged fuel/component pressure but maintained pipeline-based gross margin accretion. | Mixed Sequential gross margin eased as electronics/freight inflation replaced productivity offsets. | Watch component cost and freight commentary alongside gross margin guidance and any price increase discussion. |
| RCS portfolio management shifted mix toward higher-growth SaaS platforms | Positive Integrated RCS into global revenue and planned investment in higher-margin SaaS. | Positive Management expected mid-single-digit RCS growth through portfolio management process. | Positive RCS portfolio work was described as progressing toward reaccelerating growth in 2027. | Positive MatrixCare divestiture framed as accelerating RCS mix and profitability. | Monitor RCS growth rate commentary and update on MatrixCare transition-service impacts. |
| New asset integration: Noctrix and broader sleep-device roadmap | Positive Noctrix acquisition announced as higher-growth, higher-margin RLS device add-on. | Positive Noctrix integration began and guided around EPS dilution from the deal. | Track EPS dilution terms and how Noctrix reimbursed adoption flows through HME/DME channel. |
| Portfolio capital and capacity investments balanced with shareholder returns | Positive Management tied free cash flow flexibility to buybacks and growth investments. | Positive Share repurchases increased, while mgmt reinforced ongoing R&D and marketing allocation. | Positive Returned capital alongside $520M free cash flow and operational margin expansion. | Mixed Accelerating 2027 buybacks and dividend growth coexisted with recall-related headwinds. | Monitor FY2027 capital expenditures guidance and any additional recall/field-action cost disclosures. |
Management reported multiple increases in CME participation and intended behavior change, and linked education to increased assessments/diagnoses and VirtualOx activity as the pathway scales.
ResMed described integrating RCS into global revenue and investing more in higher-growth, higher-margin SaaS while reducing exposure to lower-growth services. Q4 tied further actions to the MatrixCare divestiture plan.
In Q4, management attributed sequential gross margin decline to increased inflation in electronics components and freight, with a smaller FX contribution versus stronger prior-quarter productivity offsets.
Management’s FY2027 guidance incorporated MatrixCare-related headwinds and transition service agreements intended to offset stranded costs in year one, implying earnings sensitivity during integration/divestiture execution.
Q4 included a $42M provision and management described a $75M FY2027 headwind via a $0.15 EPS impact embedded in core EPS growth, alongside suspension of new Astral sales for FY2027.
Across Q1–Q3, management described the patient funnel as non-linear, with correlations from claims and channel checks but ongoing work to quantify contributions by demand source to conversion.
Scroll horizontally to see more columns.
| Quarter | Revenue | YoY revenue growth | Diluted EPS | Gross margin | Investor read |
|---|---|---|---|---|---|
| Q1Sep-25 | $1.34B | -0.9% | $2.37 | 61.5% | Q1 combined mask innovation, RCS portfolio changes, and operating leverage—supporting mgmt confidence in reaccelerating categories later in FY2026. |
| Q2Dec-25 | $1.42B | 6.5% | $2.68 | 62.2% | Q2 reinforced operating leverage through gross margin expansion while management described portfolio management continuing to support RCS improvement into FY2027. |
| Q3Mar-26 | $1.43B | 0.6% | $2.71 | 62.2% | Q3 also highlighted ongoing supply chain resilience and continued portfolio management progress toward reaccelerating RCS while integrating new sleep-device growth. |
| Q4Jun-26 | $1.46B | 2.3% | $2.37 | 58.4% | Q4 also framed FY2027 as core sleep volume growth with modest price actions and productivity offsets, alongside accelerated capital returns. |
Management leaned into real-world adherence data for fabric masks and reiterated GLP-1/PAP resupply outcomes, while also introducing Noctrix as a tuck-in to extend sleep-device reach beyond sleep apnea and insomnia. Supply chain resilience remained a key message amid component and fuel pressures.
Read earnings transcriptIn the year’s closing quarter, management added more detail to the ecosystem (AirSense 11 rollout, AI coaching engagement) and executed portfolio actions (MatrixCare divestiture, Noctrix integration). FY2027 guidance included a $75M Astral headwind and modest price assumptions alongside productivity.
Read earnings transcriptFollow quarter-by-quarter adherence/compliance commentary for AirTouch masks and assess consistency across regions and channels.
Management acknowledged sequential gross margin drag when inflation in electronics components and freight exceeded productivity offsets.
Monitor gross margin guidance trajectory, freight/component cost commentary, and whether price increases become more than “modest.”
Portfolio divestiture and transition service agreements can affect the timing of RCS revenue growth and operating leverage through FY2027.
Watch management updates on transition service agreement impacts and whether RCS returns to high-single-digit growth as planned.
Management embedded a $75M FY2027 headwind and cited a $42M Q4 provision; this can influence earnings path and execution priorities.
Listen for additional field safety notice cost updates and any changes to Astral sales suspension or accrual assumptions.
Dafinchi